FDA clears Shimadzu hybrid CT
Shimadzu Medical Systems has highhopes for its new SCT-4800 line of CT scanners. The vendor hasalready sold 10 systems in the U.S. since the Food and Drug Administrationcleared the line in July. Shimadzu is targeting sales of 40 systemsin the U.S. and
Shimadzu Medical Systems has highhopes for its new SCT-4800 line of CT scanners. The vendor hasalready sold 10 systems in the U.S. since the Food and Drug Administrationcleared the line in July. Shimadzu is targeting sales of 40 systemsin the U.S. and 400 worldwide by March 1995, according to DonKarle, marketing manager of CT and MRI for the Torrance, CA-basedvendor.
Shimadzu unveiled the SCT-4800 series at last year's RadiologicalSociety of North America conference (SCAN 11/17/94). The seriesincludes SCT-4800TF, a higher end scanner, and SCT-4800TE. Bothsystems are non-spiral scanners and list below $500,000.
The 4800 line is unique in that its x-ray generator can powerboth the CT scanner and a radiographic room. This is an addedplus in developing countries such as those in southeast Asia,according to Karle. The scanners are marketed outside the U.S.as Intellect FXT and Intellect EXT.
In other Shimadzu news, MRI director Mark Silverman has leftthe company. Silverman was brought on in an attempt to jump-startShimadzu's MRI effort (SCAN 7/28/93). Shimadzu decided to scaleback its MRI sales program earlier this year, and Silverman waslet go as part of that restructuring (SCAN 7/13/94). Karle willassume Silverman's responsibilities.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
